NIAID Site Search

The purpose of this study is to see if vorinostat is safe for people with moderate-to-severe CD and to see if it is safe for people with moderate-to-sever CD to receive maintenance therapy using Ustekinumab after successful treatment of Vorinostat.

NIAID postbac Kimberly Manalang received the top score for her talk at the 2024 NIAID TmT Competition last month. She will represent the institute in the NIH-wide TmT Competition on June 27. Learn about her experience participating and her preparation for her winning talk.

Published: June 3, 2024

Last Reviewed: August 6, 2024

This PDF provides a tool for evaluating organization review, coordinate and maintain oversight of all applications and proposal

Last Reviewed: November 26, 2019

Office of Research on Women’s Health and NIH Support for Research on Women’s Health Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2019–2020 508-compliant PDF

Last Reviewed: March 8, 2022

This WORD document provides a tool for evaluating organization review, coordinate and maintain oversight of all applications and proposal

Last Reviewed: August 6, 2019

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002